Enterprise Value
42.67M
Cash
29.0M
Avg Qtr Burn
-5.201M
Short % of Float
0.11%
Insider Ownership
9.89%
Institutional Own.
52.04%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NX-13 Details Ulcerative colitis | Phase 2 Data readout | |
LABP-104 Details Systemic lupus erythematosus | Failed Discontinued | |
Omilancor (BT-11) Details Crohns disease | Failed Discontinued | |
LABP-104 Details Rheumatoid arthritis | Failed Discontinued | |
Omilancor (BT-11) Details Ulcerative colitis | Failed Discontinued | |
Omilancor Details Eosinophilic Esophagitis | Failed Discontinued | |
NX-13 Details Crohns disease | Failed Discontinued | |
Omilancor (BT-11) Details Atopic dermatitis | Failed Discontinued |